Combination Therapies to Improve Immune-Mediated Approaches for Osteosarcoma episode artwork

EPISODE · Aug 12, 2022 · 58 MIN

Combination Therapies to Improve Immune-Mediated Approaches for Osteosarcoma

from MIB Agents OsteoBites and osTEAo · host MIB Agents Osteosarcoma

Dr. Yustein is a pediatric oncologist and physician-scientist with significant training in molecular and cellular biology. During his time as the Director of the Faris D. Ewing Sarcoma Center at Texas Children's Hospital, he recognized the need for improving our understanding of the molecular pathogenesis of sarcomas and the identification of new therapeutic avenues, especially for patients with therapeutic resistant and/or metastatic disease. His laboratory has tremendous interest and experience in merging innovative murine models and patient-derived resources towards garnering molecular insights into sarcoma initiation, development/resistance and metastatic progression and translating these findings towards testing novel therapeutic interventions for these aggressive malignancies. His laboratory has developed and characterized robust metastatic genetically engineered mouse models (GEMM) for pediatric sarcomas, including osteosarcoma (OS), which recapitulate the human disease initiation and progression. Subsequently, his lab has derived primary sarcoma lines from the GEMM tumors that can be orthotopically transplanted into wild type C57BL/6 mice and monitored using in vivo imaging for further characterization of sarcoma development and progression. He recently moved to Atlanta to join Emory University as a Professor in the Department of Pediatrics, Hematology-Oncology Division and the Director of Solid Tumor Translational Research Children’s Healthcare of Atlanta and the Aflac Cancer and Blood Disorders Center. --- What We Do at MIB Agents: PROGRAMS: ✨ End-of-Life MISSIONS ✨ Gamer Agents ✨ Agent Writers ✨ Prayer Agents ✨ Healing Hearts - Bereaved Parent Support ✨ Ambassador Agents - Peer Support ✨ Warrior Mail ✨ Young Adult Survivorship Support Group ✨  EDUCATION for physicians, researchers and families: ✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma ✨ MIB Book: Osteosarcoma: From our Families to Yours ✨ RESEARCH: Annual MIB FACTOR Research Conference ✨ Funding $100,000 annually for OS research ✨ MIB Testing & Research Directory ✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter. 🔗 https://www.mibagents.org​ Help support MIB Agents, Donate here https://www.mibagents.org/?form=donate ✨✨SUBSCRIBE for all the Osteosarcoma Intel ✨✨

Episode metadata supplied by the publisher feed · Published Aug 12, 2022

Embed this episode

NOW PLAYING

Combination Therapies to Improve Immune-Mediated Approaches for Osteosarcoma

0:00 58:00

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of MIB Agents OsteoBites and osTEAo?

This episode is 58 minutes long.

When was this MIB Agents OsteoBites and osTEAo episode published?

This episode was published on August 12, 2022.

Can I download this MIB Agents OsteoBites and osTEAo episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!